◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

BriaCell Therapeutics Corp.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item FY 2024Jul 31, 2024 FY 2023Jul 31, 2023 FY 2022Jul 31, 2022 FY 2021Jul 31, 2021
Total Revenue 0.00 0.00 0.00 0.00
Operating Revenue 0.00 0.00 0.00 0.00
Selling General And Administration 6.2M 7.9M 7.3M 5.0M
General And Administrative Expense 6.2M 7.9M 7.3M 5.0M
Research And Development 27.2M 15.3M 8.0M 2.0M
Depreciation And Amortization In Income Statement -- -- -- 15,254
Other Operating Expenses -- -- -3,388 -3,691
Operating Expense 33.3M 23.3M 15.3M 7.0M
Operating Income -33.3M -23.3M -15.3M -7.0M
EBIT -4.9M -23.3M -26.8M -13.7M
Interest Expense -- 0.00 979.00 78,554
Interest Expense Non Operating -- 0.00 979.00 78,554
Interest Income 288,018 891,213 136,731 3,149
Interest Income Non Operating 288,018 891,213 136,731 3,149
Net Interest Income 288,018 891,213 135,752 -75,405
Other Income Expense 28.1M 2.1M -11.7M -6.8M
Special Income Charges -- -- 0.00 -141,703
Gain On Sale Of Security 28.2M 2.1M -11.7M -6.6M
Earnings From Equity Interest -106,510 0.00 -- --
Pretax Income -4.9M -20.3M -26.8M -13.8M
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -4.8M -20.3M -26.8M -13.8M
Net Income From Continuing Operation Net Minority Interest -4.8M -20.3M -26.8M -13.8M
Net Income Including Noncontrolling Interests -4.9M -20.3M -26.8M -13.8M
Minority Interests 140,082 0.00 -- --
Net Income Common Stockholders -4.8M -20.3M -26.8M -13.8M
Net Income -4.8M -20.3M -26.8M -13.8M
EBITDA -4.8M -23.3M -26.8M -13.7M
Normalized EBITDA -33.1M -25.3M -15.1M -7.0M
Reconciled Depreciation 83,897 15,271 15,272 15,256
Basic EPS -43.68 -195.00 -259.50 -13.50
Diluted EPS -43.68 -195.00 -259.50 -13.50
Basic Average Shares 109,699 104,131 103,293 30,130
Diluted Average Shares 109,699 104,131 103,293 30,130
Total Unusual Items 28.2M 2.1M -11.7M -6.8M
Total Unusual Items Excluding Goodwill 28.2M 2.1M -11.7M -6.8M
Tax Rate For Calcs 0.00 0.00 0.00 0.00
Normalized Income -33.0M -22.4M -15.1M -7.0M
Amortization -- -- -- 15,254
Amortization Of Intangibles Income Statement -- -- -- 15,254
Depreciation Amortization Depletion Income Statement -- -- -- 15,254
Depreciation Income Statement -- -- -- 15,254
Diluted NI Availto Com Stockholders -4.8M -20.3M -26.8M -13.8M
Insurance And Claims -- -- -- 318,034
Net Income Continuous Operations -4.9M -20.3M -26.8M -13.8M
Net Non Operating Interest Income Expense 288,018 891,213 135,752 -75,405
Other Gand A 6.2M 7.9M 7.3M 5.0M
Other Special Charges -- -- -- 141,703
Rent And Landing Fees -- -- -- 11,939
Rent Expense Supplemental -- -- -- 11,939
Salaries And Wages -- -- -- 2.1M
Total Expenses 33.3M 23.3M 15.3M 7.0M
Total Operating Income As Reported -33.3M -23.3M -15.3M -7.0M
Total Other Finance Cost -- -- 11.7M 4.4M
Line Item FY 2024Jul 31, 2024 FY 2023Jul 31, 2023 FY 2022Jul 31, 2022 FY 2021Jul 31, 2021
Cash And Cash Equivalents 862,089 21.3M 41.0M 57.3M
Cash Cash Equivalents And Short Term Investments 862,089 21.3M 41.0M 57.3M
Cash Financial -- -- -- 57.3M
Accounts Receivable -- 18,873 24,103 12,574
Receivables 1.4M 717,742 24,103 12,574
Prepaid Assets 1.4M 5.0M 1.3M 516,891
Current Assets 3.7M 26.9M 42.3M 57.8M
Gross PPE 456,801 0.00 -- --
Accumulated Depreciation -68,626 0.00 -- --
Net PPE 388,175 0.00 -- --
Goodwill And Other Intangible Assets 199,796 215,068 230,339 245,610
Other Intangible Assets 199,796 215,068 230,339 245,610
Investments And Advances 418,490 2.00 2.00 2.00
Long Term Equity Investment 418,490 0.00 -- --
Total Non Current Assets 2.2M 215,070 230,341 245,612
Total Assets 5.9M 27.2M 42.6M 58.0M
Accounts Payable 7.2M 1.1M 463,280 214,116
Payables 7.2M 1.1M 463,280 295,083
Payables And Accrued Expenses 7.5M 1.8M 941,087 556,795
Current Accrued Expenses 290,376 677,718 477,807 261,712
Current Liabilities 7.5M 1.8M 941,087 556,795
Long Term Debt -- -- -- 25,986
Long Term Debt And Capital Lease Obligation -- -- -- 25,986
Total Non Current Liabilities Net Minority Interest 1.1M 29.1M 31.3M 29.8M
Total Liabilities Net Minority Interest 8.6M 30.9M 32.2M 30.4M
Common Stock 72.2M 69.6M 65.6M 54.8M
Capital Stock 72.2M 69.6M 65.6M 54.8M
Additional Paid In Capital -- 7.4M 5.2M 2.2M
Retained Earnings -85.4M -80.7M -60.3M -29.1M
Gains Losses Not Affecting Retained Earnings -138,684 -138,684 -138,684 -138,684
Other Equity Adjustments -138,684 -138,684 -138,684 -138,684
Common Stock Equity -2.4M -3.8M 10.3M 27.7M
Stockholders Equity -2.4M -3.8M 10.3M 27.7M
Total Equity Gross Minority Interest -2.7M -3.8M 10.3M 27.7M
Minority Interest -302,522 0.00 -- --
Total Capitalization -2.4M -3.8M 10.3M 27.7M
Net Tangible Assets -2.6M -4.0M 10.1M 27.4M
Tangible Book Value -2.6M -4.0M 10.1M 27.4M
Working Capital -3.8M 25.1M 41.4M 57.2M
Invested Capital -2.4M -3.8M 10.3M 27.7M
Total Debt -- -- -- 25,986
Share Issued 121,897 106,544 103,453 101,797
Ordinary Shares Number 121,897 106,544 103,453 101,797
Derivative Product Liabilities 1.1M 29.1M 31.3M 29.8M
Investmentsin Subsidiariesat Cost 418,490 0.00 -- --
Non Current Prepaid Assets 1.2M 0.00 -- --
Other Equity Interest 11.0M 7.4M -- 18.4M
Other Payable -- -- -- 80,967
Other Properties 456,801 -- -- --
Other Receivables 1.4M 717,742 -- --
Line Item FY 2024Jul 31, 2024 FY 2023Jul 31, 2023 FY 2022Jul 31, 2022 FY 2021Jul 31, 2021
Operating Cash Flow -24.1M -23.7M -12.5M -7.8M
Cash Flow From Continuing Operating Activities -24.1M -23.7M -12.5M -7.8M
Depreciation And Amortization 83,897 15,271 15,272 15,256
Depreciation Amortization Depletion 83,897 15,271 15,272 15,256
Stock Based Compensation 1.8M 2.2M 3.1M 2.0M
Change In Working Capital 7.1M -3.5M -391,292 -2.3M
Change In Receivables -732,578 5,230 -11,530 9,941
Change In Payables And Accrued Expense 5.7M 860,370 384,292 -2.2M
Change In Payable 6.0M 660,459 249,164 -1.4M
Other Non Cash Items -- -- -2,409 1.9M
Capital Expenditure -456,801 -- -- --
Purchase Of PPE -456,801 0.00 -- --
Net PPE Purchase And Sale -456,801 0.00 -- --
Purchase Of Business -225,000 0.00 -- --
Net Investment Purchase And Sale -- -- -- 0.00
Investing Cash Flow -681,801 0.00 -- 0.00
Cash Flow From Continuing Investing Activities -681,801 0.00 -- 0.00
Issuance Of Debt -- -- 0.00 215,710
Repayment Of Debt -- -- 0.00 -546,108
Net Issuance Payments Of Debt -- -- 0.00 -330,398
Issuance Of Capital Stock 4.4M 4.0M 0.00 51.6M
Repurchase Of Capital Stock 0.00 -47,294 -10.2M 0.00
Net Common Stock Issuance 4.4M 4.0M -10.2M 51.6M
Common Stock Payments 0.00 -47,294 -10.2M 0.00
Financing Cash Flow 4.4M 4.0M -3.7M 65.0M
Cash Flow From Continuing Financing Activities 4.4M 4.0M -3.7M 65.0M
Effect Of Exchange Rate Changes -- -- -- 0.00
Changes In Cash -20.4M -19.8M -16.2M 57.2M
Beginning Cash Position 21.3M 41.0M 57.3M 21,249
End Cash Position 862,089 21.3M 41.0M 57.3M
Free Cash Flow -24.6M -23.7M -12.5M -7.8M
Amortization Cash Flow 15,271 15,271 15,272 --
Amortization Of Intangibles 15,271 15,271 15,272 --
Change In Account Payable 6.0M 660,459 249,164 -1.4M
Change In Accrued Expense -387,339 199,911 135,128 -785,399
Change In Prepaid Assets 2.1M -4.4M -764,054 -100,984
Common Stock Issuance 4.4M 4.0M 0.00 51.6M
Depreciation 68,626 0.00 -- --
Earnings Losses From Equity Investments 106,510 0.00 -- --
Gain Loss On Investment Securities -28.2M -2.1M 11.7M 4.4M
Long Term Debt Issuance -- -- -- 215,710
Long Term Debt Payments -- -- -- -309,645
Net Business Purchase And Sale -225,000 0.00 -- --
Net Foreign Currency Exchange Gain Loss -- -- -- 0.00
Net Income From Continuing Operations -4.9M -20.3M -26.8M -13.8M
Net Long Term Debt Issuance -- -- -- -93,935
Net Other Financing Charges -- -- -80,693 --
Net Short Term Debt Issuance -- -- 0.00 -330,398
Operating Gains Losses -28.1M -2.1M 11.7M 4.5M
Proceeds From Stock Option Exercised 0.00 1,594 6.5M 13.7M
Short Term Debt Issuance -- -- 0.00 215,710
Short Term Debt Payments -- -- 0.00 -546,108
NEWS
Loading news...
TRENDING
Loading...